ChimeriVax-Japanese encephalitis: Phase II

ACM said that in an open-label U.S. Phase II trial of its ChimeriVax-JE vaccine in 20 volunteers, 6 of

Read the full 191 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE